STARPHARMA HOLDINGS LIMITED - Announcements

0.00%

13.0¢

Market Cap $54.36M

Healthcare Biotechnology

Starpharma Holdings Limited is an Australia-based biotechnology company. The principal... Starpharma Holdings Limited is an Australia-based biotechnology company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. It has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

SPL	Annual report and full year financial results	PRICE SENSITIVE	29/08/11	1.48MB	Share
SPL	GSK awarded funds for dermal treatment with SPL's dendrimers	PRICE SENSITIVE	22/08/11	47.49KB	Share
ANN +SPL	SPL terminates Reckitt agreement and signs with Ansell	PRICE SENSITIVE	17/08/11	196.49KB	Share
SPL	SPL Commences VivaGel Bacterial Vaginosis Prevention Study	PRICE SENSITIVE	15/08/11	173.03KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	28/07/11	155.22KB	Share
SPL	Starpharma advances agrochemical program	PRICE SENSITIVE	12/07/11	243.24KB	Share
SPL	Advances leading cancer therapeutic in drug delivery program	PRICE SENSITIVE	29/06/11	251.98KB	Share
SPL	VivaGel Demonstrates Efficacy in Bacterial Vaginosis	PRICE SENSITIVE	23/05/11	172.31KB	Share
SPL	VivaGel Coated Condom Licence Agreement with Okamoto Japan	PRICE SENSITIVE	10/05/11	188.75KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	27/04/11	153.36KB	Share
SPL	Completes enrolment for Phase 2 study of VivaGel for BV	PRICE SENSITIVE	23/03/11	149.02KB	Share
SPL	SPL to expand agricultural program through $250,000 funding	PRICE SENSITIVE	03/03/11	140.04KB	Share
SPL	Half Yearly Report and Accounts	PRICE SENSITIVE	21/02/11	705.75KB	Share
SPL	Response to ASX Query	PRICE SENSITIVE	09/02/11	91.14KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/11	59.55KB	Share
SPL	Response to an ASX Price Query	PRICE SENSITIVE	18/11/10	101.08KB	Share
SPL	Starpharma's partner SSL acquired by Reckitt Benckiser	PRICE SENSITIVE	04/11/10	38.73KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	25/10/10	60.38KB	Share
SPL	Starpharma Expands Lilly Partnership	PRICE SENSITIVE	30/09/10	15.5KB	Share
SPL	Annual Report and full year financial results	PRICE SENSITIVE	25/08/10	1.25MB	Share
SPL	VivaGel condom patent grant extends coverage	PRICE SENSITIVE	18/08/10	25.97KB	Share
SPL	Starpharma announces Phase 2 BV study of VivaGel	PRICE SENSITIVE	16/08/10	25.73KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/10	63.21KB	Share
SPL	Starpharma's Bacterial Vaginosis Study gets FDA Clearance	PRICE SENSITIVE	15/07/10	83.8KB	Share
SPL	SPL and Monash University collaboration receives ARC grant	PRICE SENSITIVE	29/06/10	26.07KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	27/04/10	52.84KB	Share
SPL	Successful completion of VivaGel study sexually active women	PRICE SENSITIVE	12/03/10	39.69KB	Share
SPL	Half Yearly Report and Accounts	PRICE SENSITIVE	18/02/10	261.89KB	Share
SPL	Starpharma and Lilly Sign New Drug Delivery Collaboration	PRICE SENSITIVE	01/02/10	23.5KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/10	42.9KB	Share
SPL	Starpharma announces $15.6 million capital raising	PRICE SENSITIVE	18/11/09	27.69KB	Share
SPL	Reinstatement to Official Quotation	PRICE SENSITIVE	18/11/09	23.43KB	Share
SPL	Suspension from Official Quotation	PRICE SENSITIVE	16/11/09	47.25KB	Share
SPL	Trading Halt	PRICE SENSITIVE	12/11/09	39.97KB	Share
SPL	Starpharma signs agrochemicals deal	PRICE SENSITIVE	05/11/09	25.77KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	23/10/09	61.4KB	Share
SPL	US Patent Grant Extends VivaGel Coverage to 2024	PRICE SENSITIVE	22/09/09	24.5KB	Share
SPL	Preliminary Final Report	PRICE SENSITIVE	24/08/09	509.96KB	Share
SPL	Interim Financial Results - Material Improvement	PRICE SENSITIVE	04/08/09	26.32KB	Share
SPL	VivaGel - Anti-HIV and Herpes Activity following human admin	PRICE SENSITIVE	03/08/09	46.88KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/09	47.26KB	Share
SPL	Completes $7.1m capital raising	PRICE SENSITIVE	21/05/09	24.28KB	Share
SPL	Elanco deal triggers Starpharma SPP extension	PRICE SENSITIVE	11/05/09	21.71KB	Share
SPL	Starpharma and Elanco sign agreement	PRICE SENSITIVE	11/05/09	34.34KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	07/04/09	45.6KB	Share
SPL	Raises additional capital via institutional placement	PRICE SENSITIVE	07/04/09	25.46KB	Share
SPL	Trading Halt	PRICE SENSITIVE	03/04/09	18.71KB	Share
SPL	Completes patient testing in retention of activity study	PRICE SENSITIVE	19/03/09	40.14KB	Share
SPL	Half Yearly Report and Accounts	PRICE SENSITIVE	19/02/09	227.84KB	Share
SPL	Topical Microbicide Field Boost With Efficacy Result	PRICE SENSITIVE	10/02/09	25.06KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/09	42.89KB	Share
SPL	Starpharma Dendrimer Reduces Toxicity of Cancer Drug	PRICE SENSITIVE	17/12/08	37.47KB	Share
SPL	SPL7013 activity against all major HPV strains	PRICE SENSITIVE	04/12/08	25.6KB	Share

SPLAnnual report and full year financial results
29/08/11	PRICE SENSITIVE	1.48MB	Share
SPLGSK awarded funds for dermal treatment with SPL's dendrimers
22/08/11	PRICE SENSITIVE	47.49KB	Share
ANN +SPLSPL terminates Reckitt agreement and signs with Ansell
17/08/11	PRICE SENSITIVE	196.49KB	Share
SPLSPL Commences VivaGel Bacterial Vaginosis Prevention Study
15/08/11	PRICE SENSITIVE	173.03KB	Share
SPLAppendix 4C - quarterly
28/07/11	PRICE SENSITIVE	155.22KB	Share
SPLStarpharma advances agrochemical program
12/07/11	PRICE SENSITIVE	243.24KB	Share
SPLAdvances leading cancer therapeutic in drug delivery program
29/06/11	PRICE SENSITIVE	251.98KB	Share
SPLVivaGel Demonstrates Efficacy in Bacterial Vaginosis
23/05/11	PRICE SENSITIVE	172.31KB	Share
SPLVivaGel Coated Condom Licence Agreement with Okamoto Japan
10/05/11	PRICE SENSITIVE	188.75KB	Share
SPLAppendix 4C - quarterly
27/04/11	PRICE SENSITIVE	153.36KB	Share
SPLCompletes enrolment for Phase 2 study of VivaGel for BV
23/03/11	PRICE SENSITIVE	149.02KB	Share
SPLSPL to expand agricultural program through $250,000 funding
03/03/11	PRICE SENSITIVE	140.04KB	Share
SPLHalf Yearly Report and Accounts
21/02/11	PRICE SENSITIVE	705.75KB	Share
SPLResponse to ASX Query
09/02/11	PRICE SENSITIVE	91.14KB	Share
SPLAppendix 4C - quarterly
31/01/11	PRICE SENSITIVE	59.55KB	Share
SPLResponse to an ASX Price Query
18/11/10	PRICE SENSITIVE	101.08KB	Share
SPLStarpharma's partner SSL acquired by Reckitt Benckiser
04/11/10	PRICE SENSITIVE	38.73KB	Share
SPLAppendix 4C - quarterly
25/10/10	PRICE SENSITIVE	60.38KB	Share
SPLStarpharma Expands Lilly Partnership
30/09/10	PRICE SENSITIVE	15.5KB	Share
SPLAnnual Report and full year financial results
25/08/10	PRICE SENSITIVE	1.25MB	Share
SPLVivaGel condom patent grant extends coverage
18/08/10	PRICE SENSITIVE	25.97KB	Share
SPLStarpharma announces Phase 2 BV study of VivaGel
16/08/10	PRICE SENSITIVE	25.73KB	Share
SPLAppendix 4C - quarterly
27/07/10	PRICE SENSITIVE	63.21KB	Share
SPLStarpharma's Bacterial Vaginosis Study gets FDA Clearance
15/07/10	PRICE SENSITIVE	83.8KB	Share
SPLSPL and Monash University collaboration receives ARC grant
29/06/10	PRICE SENSITIVE	26.07KB	Share
SPLAppendix 4C - quarterly
27/04/10	PRICE SENSITIVE	52.84KB	Share
SPLSuccessful completion of VivaGel study sexually active women
12/03/10	PRICE SENSITIVE	39.69KB	Share
SPLHalf Yearly Report and Accounts
18/02/10	PRICE SENSITIVE	261.89KB	Share
SPLStarpharma and Lilly Sign New Drug Delivery Collaboration
01/02/10	PRICE SENSITIVE	23.5KB	Share
SPLAppendix 4C - quarterly
29/01/10	PRICE SENSITIVE	42.9KB	Share
SPLStarpharma announces $15.6 million capital raising
18/11/09	PRICE SENSITIVE	27.69KB	Share
SPLReinstatement to Official Quotation
18/11/09	PRICE SENSITIVE	23.43KB	Share
SPLSuspension from Official Quotation
16/11/09	PRICE SENSITIVE	47.25KB	Share
SPLTrading Halt
12/11/09	PRICE SENSITIVE	39.97KB	Share
SPLStarpharma signs agrochemicals deal
05/11/09	PRICE SENSITIVE	25.77KB	Share
SPLAppendix 4C - quarterly
23/10/09	PRICE SENSITIVE	61.4KB	Share
SPLUS Patent Grant Extends VivaGel Coverage to 2024
22/09/09	PRICE SENSITIVE	24.5KB	Share
SPLPreliminary Final Report
24/08/09	PRICE SENSITIVE	509.96KB	Share
SPLInterim Financial Results - Material Improvement
04/08/09	PRICE SENSITIVE	26.32KB	Share
SPLVivaGel - Anti-HIV and Herpes Activity following human admin
03/08/09	PRICE SENSITIVE	46.88KB	Share
SPLAppendix 4C - quarterly
27/07/09	PRICE SENSITIVE	47.26KB	Share
SPLCompletes $7.1m capital raising
21/05/09	PRICE SENSITIVE	24.28KB	Share
SPLElanco deal triggers Starpharma SPP extension
11/05/09	PRICE SENSITIVE	21.71KB	Share
SPLStarpharma and Elanco sign agreement
11/05/09	PRICE SENSITIVE	34.34KB	Share
SPLAppendix 4C - quarterly
07/04/09	PRICE SENSITIVE	45.6KB	Share
SPLRaises additional capital via institutional placement
07/04/09	PRICE SENSITIVE	25.46KB	Share
SPLTrading Halt
03/04/09	PRICE SENSITIVE	18.71KB	Share
SPLCompletes patient testing in retention of activity study
19/03/09	PRICE SENSITIVE	40.14KB	Share
SPLHalf Yearly Report and Accounts
19/02/09	PRICE SENSITIVE	227.84KB	Share
SPLTopical Microbicide Field Boost With Efficacy Result
10/02/09	PRICE SENSITIVE	25.06KB	Share
SPLAppendix 4C - quarterly
30/01/09	PRICE SENSITIVE	42.89KB	Share
SPLStarpharma Dendrimer Reduces Toxicity of Cancer Drug
17/12/08	PRICE SENSITIVE	37.47KB	Share
SPLSPL7013 activity against all major HPV strains
04/12/08	PRICE SENSITIVE	25.6KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 13.0¢		Change 0.000(0.00%)		Mkt cap ! $54.36M

Open	High	Low	Value	Volume
13.5¢	13.5¢	13.0¢	$66.89K	513.9K

Buyers (Bids)

No.	Vol.	Price($)
4	221560	12.5¢

Sellers (Offers)

Price($)	Vol.	No.
13.5¢	224531	9

View Market Depth

No.	Vol.	Price($)
4	221560	0.125
3	120252	0.120
3	138350	0.115
2	9099	0.110
3	106433	0.105

Price($)	Vol.	No.
0.135	224531	9
0.140	155588	4
0.145	65835	6
0.150	175000	3
0.155	74523	3

Last trade - 13.53pm 08/09/2025 (20 minute delay)


Last 13.0¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
13.0¢	13.3¢	12.5¢	284444
Last updated 13.53pm 08/09/2025 ?

SPL (ASX) Chart

STARPHARMA HOLDINGS LIMITED - Announcements

Corporate Spotlight
Not Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Clean energy vehicles with hydrogen production and distribution all under one roof

Prospect Resources continues to advance Mumbezhi project

Leeuwin Metals set to unlock significant gold potential at Marda

Haranga Resources: From uranium in Senegal to gold in the US

Top Stories

STARPHARMA HOLDINGS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Clean energy vehicles with hydrogen production and distribution all under one roof

Prospect Resources continues to advance Mumbezhi project

Leeuwin Metals set to unlock significant gold potential at Marda

Haranga Resources: From uranium in Senegal to gold in the US

Top Stories

Corporate Spotlight
Not Yet Available